WO2007039775A1 - Measurement of the total antioxidant capacity in liquids and solutions using tmb - Google Patents
Measurement of the total antioxidant capacity in liquids and solutions using tmb Download PDFInfo
- Publication number
- WO2007039775A1 WO2007039775A1 PCT/GR2006/000053 GR2006000053W WO2007039775A1 WO 2007039775 A1 WO2007039775 A1 WO 2007039775A1 GR 2006000053 W GR2006000053 W GR 2006000053W WO 2007039775 A1 WO2007039775 A1 WO 2007039775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antioxidant capacity
- tmb
- total antioxidant
- sample
- antioxidants
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 49
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 35
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 238000005259 measurement Methods 0.000 title abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 15
- 150000001768 cations Chemical class 0.000 claims abstract description 10
- 238000004042 decolorization Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 abstract description 3
- 238000006479 redox reaction Methods 0.000 abstract description 3
- 230000001603 reducing effect Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 2
- 238000002798 spectrophotometry method Methods 0.000 abstract description 2
- -1 3,3',5,5'-Tetramethylbenzidine (TMB) cation Chemical class 0.000 abstract 1
- 238000004445 quantitative analysis Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 40
- 239000000243 solution Substances 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002824 redox indicator Substances 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000003244 pro-oxidative effect Effects 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Definitions
- the present invention concerns a method of determining the total antioxidant capacity of a sample by using TMB cation solution.
- the total antioxidant capacity of a sample is determined by the reduction (decolourization) of TMB cation.
- the results compared with the reducing action of uric acid with known concentration give values expressed in ⁇ mol/litre.
- ROS reactive oxygen species
- ROS reactive oxygen species
- OH hydroxyl radical
- O 2 superoxide radical
- NO nitric oxide radical
- LOO lipid peroxyl radical
- ROS can readily react with and damage other molecules that in some cases, the body uses this to fight infections, or in other cases, the damage may be to the body's own molecules such as DNA, lipid, proteins and carbohydrates (Stadtman, E. R. Annu. Rev. Biochem. (1993), 62:797- 821).
- the antioxidants were defined as enzymes or molecules that can retard or prevent the damaging effects of ROS in tissues.
- Antioxidants have thus become a topic of increasing interest recently and the number of publications has nearly quadrupled in the past decade (Based on the Web of Knowledge search on articles containing the word antioxidant or antioxidants).
- Plasma (or serum) concentrations of different antioxidants can be measured in laboratories separately, but the measurements are time-consuming, labor-intensive, costly and they require complicated techniques. Because the measurement of different antioxidant molecules separately, is not practical and antioxidant effects of them are additive, total antioxidant response (TAR) of a sample is measured and this is named as total antioxidant capacity Miller NJ, et al., Clin Sci (Lond). (1993), Apr; 84(4):407-12); (Re R, et al. Free Radic Biol Med.
- the invention seeks to provide a method of determining the total antioxidant capacity of a liquid and/or solution by using a marker consisting of a stable substance and by providing values expressed in ⁇ mol/litre.
- redox indicator is sued hereafter to denote the oxidant in such redox reactions.
- Redox indicators are known to undergo physiochemical change, for example a colour change, when reduced by antioxidants in a sample. This physicochemical change can be easily monitored by known methods, for example by monitoring a change in absorption, or emission, of electromagnetic radiation in a sample or by other methods that are known to monitor redox reactions.
- the method of the invention utilises the ability of antioxidants to reduce TMB cation which causes decolourization of TMB cation and hence results in a decrease in absorbance at 450 nm.
- the amount of the redox indicator reduced by the antioxidant is a reflection of the total antioxidant capacity of the antioxidant. Therefore, the total antioxidant capacity of the sample can easily be measured by recording the absorbance signal at a specific wavelength (450 nm) with reference wavelength (620 nm or 570 nm), after redox indicator/sample mixing. This absorbance is then compared with the absorbance given by a known concentration of a standard solution at the same wavelength.
- the assay used in the present invention is of use with many different types of samples. Thus it is applicable to biological fluids including mammalian serum or EDTA plasma, cerebrospinal fluid, synovial fluid or saliva.
- the assay is of further use in assaying the antioxidant capacity of tissues, cells or other materials such as foodstuffs and oils.
- Synovial fluid will provide useful information in the diagnosis and/or prognosis of arthritic or rheumatic disorders whereas CSF will provide possible implications of free radical induced nerve degeneration in the brain and spinal cord, and any possible role they may have in neural inflammation in diseased states or after injury.
- the invention can be used to determine the contribution of specific or particular classes of antioxidants known or suspected to be present in a sample, by comparing the antioxidant capacity as measured by the method of the invention before and after the specific or particular classes of antioxidants have been removed or extracted.
- the antioxidant contribution of the proteins contained within a sample may be determined by comparing the antioxidant capacity of the sample before and after the effect of proteins have been eliminated. Elimination of protein effect is achieved by mixing TMB solution with hydrochloride acid solution before adding to sample.
- the invention has application in monitoring the progress of patients suffering from the large number of diseases and infections that cause a change in the balance of pro-oxidants and antioxidants in body fluids.
- a further application of the invention is in monitoring the effectiveness of antioxidants drugs.
- the total antioxidant capacity can be monitored to provide information on the rate of recovery.
- the relative activity of different reducing agents is calculated.
- the relative activity of vitamin C, Trolox, GSH, albumin and bilirubin in compare with uric acid were about 1, 1, 1, 0.6, 2.
- GSH is an antioxidant whose concentration is low in human serum.
- the functional part of GSH as an antioxidant is the SH group, which is also present in non- protein antioxidants such as lipoic acid and some amino acids. Therefore, GSH was used here to represent the SH-group-containing non-protein compounds.
- FIG. 1 shows the rate of increase for standards solutions (the subtraction of the blank absorbance from the standards solutions absorbance at 450 nm (reference wavelength 620 or 570 nm), uric acid (filled triangles), , ascorbic acid (cross), trolox (filled circles), GSH (cross square) and bilirubin (open squares), all measured in parallel.
- FIG. 2 shows the rate of increase for standard solutions of Albumin (the subtraction of the blank absorbance from the standard solutions absorbance at 450 nm (reference wavelength 620 or 570 nm).
- the determination of the total antioxidant capacity of a sample provides the following steps:
- substrate buffer phosphate citrate buffer
- TMB.2HC1 tablet (Sigma, contain 1 mg 3,3',5,5'-Tetramethylbenzidine.2HCl) is dissolved in 10ml substrate buffer (unused TMB solution can be stored for 4 days at 4°C); 15
- hydrochloride acid solution (HC1:2N): 40ml HCl 37% is added to 150 dH 2 O and volume is adjusted up to 200ml with dH 2 O;
- ammonium persulfate 0.04 gr ammonium persulfate is dissolved in 20 10 ml distilled water, is dispensed in aliquots (80 ⁇ l) and stored at -20 0 C for six months.
- TMB cation buffer freshly prepared before using and in case that all wells of a microplate is used: in a dark bottle, to 5.5 ml of TMB solution is added 50 ⁇ l of ammonium persulfate (0.4%), incubate at room temperature for 3-5 min, 20 ml of substrate buffer is added, mixed well gently and is used immediately;
- the method described above has the advantage of using TMB cation with a typical spectrum of absorption (450 nm, reference 620 or 570 nm), thus facilitating the work of the analyst. Moreover, it allows the values to be quantified by simple comparison with a standard curve obtained by samples with a known concentration of a typical reducing agent. It can be done for a lot of samples rapidly and cost effective and ELISA reader exist in every laboratory.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A method that can be used for the measurement of the total antioxidant capacity of an organic or inorganic liquid. The antioxidant capacity is determined by the decolourization of 3,3',5,5'-Tetramethylbenzidine (TMB) cation exerted by the antioxidants of the sample .TMB cation will be decolourized by reduction in a redox reaction. The quantitative analysis of the total antioxidant capacity of the sample can be easily made by spectrophotometry at 450 nm (reference wavelength 620 or 570 nm) both by macro- and micromethods (ELISA reader) with the use of a number of reducing standard compositions with known concentrations.
Description
Measurement of the total antioxidant capacity in liquids and solutions using TMB.
Description of the invention
FIELD OF THE INVENTION
The present invention concerns a method of determining the total antioxidant capacity of a sample by using TMB cation solution. According to the invention, the total antioxidant capacity of a sample is determined by the reduction (decolourization) of TMB cation. The results compared with the reducing action of uric acid with known concentration give values expressed in μmol/litre.
BACKGROUND OF THE INVENTION In human body, reactive oxygen species (ROS, as pro-oxidants) such as the hydroxyl radical (OH), the superoxide radical (O2), the nitric oxide radical (NO ) and the lipid peroxyl radical (LOO ) are derived either from normal essential metabolic processes or from external sources such as exposure to X-rays, ozone, cigarette smoking, air pollutants and industrial chemicals (Dean, R. T., et al, Biochem. J. (1997), 324:1-18). ROS can readily react with and damage other molecules that in some cases, the body uses this to fight infections, or in other cases, the damage may be to the body's own molecules such as DNA, lipid, proteins and carbohydrates (Stadtman, E. R. Annu. Rev. Biochem. (1993), 62:797- 821). In body, there is always a balance between pro-oxidants and antioxidants and the antioxidants mop up ROS before they damage other essential molecules. The antioxidants were defined as enzymes or molecules that can retard or prevent the damaging effects of ROS in tissues. Clinical trials and epidemiological studies have established an inverse correlation between the intake of antioxidants and the occurrence of disease such as inflammation, cardiovascular disease, cancer, and aging-related disorders (Halliwell, B.; Gutteridge, J. Oxford Univ. Press, NY (1999)); (Willet,W.C, The Harvard Medical School Guide to Healthy Eating; Simon and Schuster: New York (2001)).
Antioxidants have thus become a topic of increasing interest recently and the number of publications has nearly quadrupled in the past decade (Based on the Web of Knowledge search on articles containing the word antioxidant or antioxidants). Plasma (or serum) concentrations of different antioxidants can be measured in laboratories separately, but the measurements are time-consuming, labor-intensive, costly and they require complicated techniques. Because the measurement of different antioxidant molecules separately, is not practical and antioxidant effects of them are additive, total antioxidant response (TAR) of a sample is measured and this is named as total antioxidant capacity Miller NJ, et al., Clin Sci (Lond). (1993), Apr; 84(4):407-12); (Re R, et al. Free Radic
Biol Med. (1999), May; 26(9- 10): 1231-7), total antioxidant activity , total antioxidant power, total antioxidant status , or other synonyms (Prior RL, Cao G5 Free Radic Biol Med. (1999); Dec;27(ll-12):l 173-81. Review).
To date, various methods have been developed to measure the total antioxidant capacity and each of them has advantages and disadvantages (Cao G, Prior RL. Clin Chem. (1998), Jun;44(6 Pt 1): 1309-15); (Frankel EN, Meyer AS. J Sci Food Agr (2000), 80 (13): 1925-1941 OCT. Review); (Prior RL, et al, J Agric Food Chem. (2005), May 18;53(10):4290-302. Review); (Benzie IF, Strain JJ. Anal Biochem. (1996), JuI 15;239(l):70-6). Advantage of the present invention include the following: 1) the assay can be carried out in a single step for each sample, i.e. there is no series of separate reactions required to obtain the result; 2) the apparatus required is relatively simple, easy to maintain and 3) permits several assays to be carried out simultaneously for a numbers of samples.
THE INVENTION
The invention seeks to provide a method of determining the total antioxidant capacity of a liquid and/or solution by using a marker consisting of a stable substance and by providing values expressed in μmol/litre.
It is an object of the invention to provide a simple and efficient method for measuring the total antioxidant capacity of a sample.
The term redox indicator is sued hereafter to denote the oxidant in such redox reactions. Redox indicators are known to undergo physiochemical change, for example a colour change, when reduced by antioxidants in a sample. This physicochemical change can be easily monitored by known methods, for example by monitoring a change in absorption, or emission, of electromagnetic radiation in a sample or by other methods that are known to monitor redox reactions. The method of the invention utilises the ability of antioxidants to reduce TMB cation which causes decolourization of TMB cation and hence results in a decrease in absorbance at 450 nm.
The amount of the redox indicator reduced by the antioxidant is a reflection of the total antioxidant capacity of the antioxidant. Therefore, the total antioxidant capacity of the sample can easily be measured by recording the absorbance signal at a specific wavelength (450 nm) with reference wavelength (620 nm or 570 nm), after redox indicator/sample mixing. This absorbance is then compared with the absorbance given by a known concentration of a standard solution at the same wavelength.
The assay used in the present invention is of use with many different types of samples. Thus it is applicable to biological fluids including mammalian serum or EDTA plasma, cerebrospinal fluid, synovial fluid or saliva. The assay is of further use in assaying the antioxidant capacity of tissues, cells or other materials such as foodstuffs and oils. Synovial fluid will provide useful information in the diagnosis and/or prognosis of arthritic or rheumatic disorders whereas CSF will provide possible implications of free radical induced nerve degeneration in the brain and spinal cord, and any possible role they may have in neural inflammation in diseased states or after injury.
In a further embodiment the invention can be used to determine the contribution of
specific or particular classes of antioxidants known or suspected to be present in a sample, by comparing the antioxidant capacity as measured by the method of the invention before and after the specific or particular classes of antioxidants have been removed or extracted. Thus, the antioxidant contribution of the proteins contained within a sample may be determined by comparing the antioxidant capacity of the sample before and after the effect of proteins have been eliminated. Elimination of protein effect is achieved by mixing TMB solution with hydrochloride acid solution before adding to sample. Similarly, the invention has application in monitoring the progress of patients suffering from the large number of diseases and infections that cause a change in the balance of pro-oxidants and antioxidants in body fluids.
A further application of the invention is in monitoring the effectiveness of antioxidants drugs. Thus, after administration of such a drug, the total antioxidant capacity can be monitored to provide information on the rate of recovery.
By comparing the change in absorbance for an equivalent molar concentration of different reducing agents with an equivalent molar concentration of uric acid, the relative activity of different reducing agents is calculated. The relative activity of vitamin C, Trolox, GSH, albumin and bilirubin in compare with uric acid were about 1, 1, 1, 0.6, 2.
GSH is an antioxidant whose concentration is low in human serum. However, the functional part of GSH as an antioxidant is the SH group, which is also present in non- protein antioxidants such as lipoic acid and some amino acids. Therefore, GSH was used here to represent the SH-group-containing non-protein compounds.
BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS
FIG. 1 shows the rate of increase for standards solutions (the subtraction of the blank absorbance from the standards solutions absorbance at 450 nm (reference wavelength 620 or 570 nm), uric acid (filled triangles), , ascorbic acid (cross), trolox (filled circles), GSH (cross square) and bilirubin (open squares), all measured in parallel.
FIG. 2 shows the rate of increase for standard solutions of Albumin (the subtraction of the blank absorbance from the standard solutions absorbance at 450 nm (reference wavelength 620 or 570 nm). DETAILED DESCRIPTION OF THE INVENTION
Further features and advantages of the invention will be more readily apparent from the following description of a preferred embodiment of the method. According to the invention, the determination of the total antioxidant capacity of a sample provides the following steps:
1. preparing a serial dilution of uric standard (μM ):
6000, 3000, 1500, 750, 375, 187.5, 93.75, 46.9, 23.4, 0 (blank);
5
2. preparing substrate buffer (phosphate citrate buffer):
1.455gr di-sodium hydrogen phosphate anhydrous (Na2HPO4) , 1.91gr citric acid anhydrous (C6HsO7) is dissolved in 150 ml dH2O, pH is adjusted at 5, the volume is adjusted up to 200 ml with dH2O and is stored at 4 °C; 10
3. preparing TMB solution(freshly prepared before using):
One TMB.2HC1 tablet (Sigma, contain 1 mg 3,3',5,5'-Tetramethylbenzidine.2HCl) is dissolved in 10ml substrate buffer (unused TMB solution can be stored for 4 days at 4°C); 15
4. preparing hydrochloride acid solution (HC1:2N): 40ml HCl 37% is added to 150 dH2O and volume is adjusted up to 200ml with dH2O;
5. preparing ammonium persulfate (0.4%): 0.04 gr ammonium persulfate is dissolved in 20 10 ml distilled water, is dispensed in aliquots (80 μl) and stored at -20 0C for six months.
6. pouring a 10 μl quantity of each sample, standard and blank (distilled water) into the wells of a multiwell plate;
25 7. preparing TMB cation buffer (freshly prepared before using and in case that all wells of a microplate is used): in a dark bottle, to 5.5 ml of TMB solution is added 50 μl of ammonium persulfate (0.4%), incubate at room temperature for 3-5 min, 20 ml of substrate buffer is added, mixed well gently and is used immediately;
30 8. adding 200 μl of TMB cation buffer to each well and incubating it at room temperature in dark place for 3-4 minutes;
9. adding 50 μl hydrochloride acid solution (2N) to each well; 35 10. incubate the plate for 30-45 minutes in dark place;
11. carrying out a spectrophotometry of the samples at 450 nm with reference wavelength 620 or 570 nm by an ELISA reader;
40 12. subtracting the absorbance of samples and standards from the absorbance of blank;
13. providing a hyperbolic standard curve from the values relative to the standard samples by Microsoft Excel program and obtain a equation curve for it, i.e. the sample with known concentration of uric acid used as a typical reducing agent;
45
14. calculating the values of the unknown samples on the base of the values obtained from the above standard curve that the values are expressed as reducing equivalents in μmol/litre.
15. total antioxidant power of fresh and aged (one month at -80 0C or one week at -20 0C) 50 plasma of healthy Greece adults were 900- 2000 μmol/litre (mean 1210; SD, 286; n=50).
It is self-evident from the foregoing that the method described above has the advantage of using TMB cation with a typical spectrum of absorption (450 nm, reference 620 or 570
nm), thus facilitating the work of the analyst. Moreover, it allows the values to be quantified by simple comparison with a standard curve obtained by samples with a known concentration of a typical reducing agent. It can be done for a lot of samples rapidly and cost effective and ELISA reader exist in every laboratory.
References
Dean, R. T.; Fu, S.; Stoker, R.; Davies, M. J. Biochemistry and pathology of radical- mediated protein oxidation. Biochem. J. 324:1-18; 1997.
Stadtman, E. R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu. Rev. Biochem. 62:797- 821; 1993.
Halliwell, B.; Gutteridge, J. Free radicals in biology and medicine. Oxford Univ. Press,
NY; 1999.
Willet,W.C. Eat, Drink, and be Health- The Harvard Medical School Guide to Healthy
Eating; Simon and Schuster: New York, 2001. Based on the Web of Knowledge search on articles containing the word antioxidant or antioxidants.
Miller NJ, Rice-Evans C5 Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond). 1993 Apr;84(4):407-12. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med.
1999 May;26(9-10): 1231-7.
Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods.Free Radic Biol Med. 1999 Dec;27(l 1-12):1173-81. Review. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem. 1998 Jun;44(6 Pt l):1309-15.
Frankel EN, Meyer AS. The problems of using one-dimensional methods to evaluate multifunctional food and biological antioxidants. J Sci Food Agr 80 (13): 1925-1941
OCT 2000. Review. Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005 May 18;53(10):4290-302. Review
Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996 JuI 15;239(l):70-6.
Claims
1. A method for determining the total antioxidant capacity of a liquid sample by using
TMB cation, which comprises: mixing a sample of said liquid with TMB solution; adding a hydrochloride acid solution to the obtained mixture; determining the quantity of TMB cation decolourization exerted by the antioxidants of the sample and correlating the determined quantity of the decolourization with the total antioxidant capacity of the liquid.
2. A method for determining the total antioxidant capacity of a liquid sample according to claim 1, wherein the liquid is EDTA plasma, serum, and other biological liquid.
■Ψ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20050100503 | 2005-10-03 | ||
GR20050100503A GR1005561B (en) | 2005-10-03 | 2005-10-03 | Measurement of the total antioxidant capacity in liquids and solutions by using of 3,3', 5,5', tetramethylbenzidine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007039775A1 true WO2007039775A1 (en) | 2007-04-12 |
Family
ID=37309652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GR2006/000053 WO2007039775A1 (en) | 2005-10-03 | 2006-10-03 | Measurement of the total antioxidant capacity in liquids and solutions using tmb |
Country Status (2)
Country | Link |
---|---|
GR (1) | GR1005561B (en) |
WO (1) | WO2007039775A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8317997B2 (en) | 2011-02-28 | 2012-11-27 | Institute For Molecular Medicine, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US8512548B2 (en) | 2007-05-18 | 2013-08-20 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
US9063070B2 (en) | 2007-05-18 | 2015-06-23 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
US9360446B2 (en) | 2012-10-23 | 2016-06-07 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
US9372167B2 (en) | 2012-04-19 | 2016-06-21 | Aytu Bioscience, Inc. | Oxidation-reduction potential test device including a multiple layer gel |
IT201800003475A1 (en) * | 2018-03-13 | 2019-09-13 | Fondazione St Italiano Tecnologia | Procedure for determining the antioxidant capacity of a biological sample and relative kit. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027131D0 (en) * | 1990-12-14 | 1991-02-06 | Rice Evans Catherine | Diagnostic test |
-
2005
- 2005-10-03 GR GR20050100503A patent/GR1005561B/en not_active IP Right Cessation
-
2006
- 2006-10-03 WO PCT/GR2006/000053 patent/WO2007039775A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
ALAMDARI DARYOUSH HAMIDI ET AL: "High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein.", FREE RADICAL BIOLOGY & MEDICINE. 15 NOV 2005, vol. 39, no. 10, 19 August 2005 (2005-08-19), pages 1362 - 1367, XP002407200, ISSN: 0891-5849 * |
TATZBER FRANZ ET AL: "Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera.", ANALYTICAL BIOCHEMISTRY. 15 MAY 2003, vol. 316, no. 2, 15 May 2003 (2003-05-15), pages 147 - 153, XP002397815, ISSN: 0003-2697 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9063070B2 (en) | 2007-05-18 | 2015-06-23 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
US10036723B2 (en) | 2007-05-18 | 2018-07-31 | Aytu Bioscience, Inc. | Measurement and uses of oxidative status |
US8512548B2 (en) | 2007-05-18 | 2013-08-20 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
US9423372B2 (en) | 2007-05-18 | 2016-08-23 | Aytu Bioscience, Inc. | Measurement and uses of oxidative status |
US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
US9383331B2 (en) | 2007-05-18 | 2016-07-05 | Aytu Bioscience, Inc. | Measurement and uses of oxidative status |
US9528959B2 (en) | 2011-02-28 | 2016-12-27 | Aytu Bioscience, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US9034159B2 (en) | 2011-02-28 | 2015-05-19 | Luoxis Diagnostics, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US8641888B2 (en) | 2011-02-28 | 2014-02-04 | Luoxis Diagnostics, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US8317997B2 (en) | 2011-02-28 | 2012-11-27 | Institute For Molecular Medicine, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US8329012B2 (en) | 2011-02-28 | 2012-12-11 | Institute For Molecular Medicine, Inc. | Method and apparatus for measuring oxidation-reduction potential |
US9372167B2 (en) | 2012-04-19 | 2016-06-21 | Aytu Bioscience, Inc. | Oxidation-reduction potential test device including a multiple layer gel |
US10281425B2 (en) | 2012-04-19 | 2019-05-07 | Aytu Bioscience, Inc. | Multiple layer gel |
US9360446B2 (en) | 2012-10-23 | 2016-06-07 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
US9410913B2 (en) | 2012-10-23 | 2016-08-09 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
US10184931B2 (en) | 2012-10-23 | 2019-01-22 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
IT201800003475A1 (en) * | 2018-03-13 | 2019-09-13 | Fondazione St Italiano Tecnologia | Procedure for determining the antioxidant capacity of a biological sample and relative kit. |
WO2019175749A1 (en) * | 2018-03-13 | 2019-09-19 | Fondazione Istituto Italiano Di Tecnologia | Method for determining the antioxidant capacity of a biological sample and related kit |
Also Published As
Publication number | Publication date |
---|---|
GR20050100503A (en) | 2007-05-23 |
GR1005561B (en) | 2007-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fraga et al. | In vitro measurements and interpretation of total antioxidant capacity | |
Ou et al. | Determination of total antioxidant capacity by oxygen radical absorbance capacity (ORAC) using fluorescein as the fluorescence probe: First action 2012.23 | |
Savory et al. | A biuret method for determination of protein in normal urine | |
Uy et al. | Measurement of reactive oxygen species in the culture media using Acridan Lumigen PS-3 assay | |
Mendoza-Núñez et al. | Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly | |
Al‐Shobaili et al. | Biochemical markers of oxidative and nitrosative stress in acne vulgaris: correlation with disease activity | |
Vientós-Plotts et al. | Effect of blood contamination on results of dipstick evaluation and urine protein-to-urine creatinine ratio for urine samples from dogs and cats | |
Campos et al. | Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome | |
Grigorieva et al. | Measurement of plasma hemoglobin peroxidase activity | |
WO2007039775A1 (en) | Measurement of the total antioxidant capacity in liquids and solutions using tmb | |
US6177260B1 (en) | Measurement of antioxidant (reducing) power and/or antioxidant concentration | |
US5427951A (en) | Diagnostic test for determining the antioxidant status of a sample | |
EP0097472B1 (en) | Method of determining calcium in a fluid sample | |
Thompson | Peroxidase-based colorimetric determination of L-ascorbic acid | |
Campos et al. | Urinary uric acid and antioxidant capacity in children and adults with Down syndrome | |
US20090123956A1 (en) | Measurement of the oxidants-antioxidants balance in liquids | |
US5759860A (en) | Automated analysis method for detecting bacterial nitrite in urine | |
Bunch et al. | Lead poisoning: clinical and laboratory considerations | |
Prenesti et al. | Measurement uncertainty evaluation of the Total Antioxidant Capacity of human plasma tested by the CUPRAC-BCS method | |
Ergünol et al. | Age and gender related changes on total antioxidant/oxidant status and electrolyte composition of saliva | |
Alharthi et al. | pH assists simultaneous determination of folic acid and vitamin D 3 in biological fluids using a novel Tb 3+–acyclovir optical biosensor | |
Issa et al. | Estimation of blood and urine levels of eight metals and essential trace elements collected from living Subjects compared to urine, cardiac and femoral postmortem blood, and other postmortem samples: A forensic toxicology study | |
Attia et al. | New Tb 3+–simvastatin optical biosensor for sensitive determination of folic acid, progesterone, testosterone and vitamin D 3 in biological fluids | |
Gültepe et al. | Assessment of iodine intake in mildly iodine-deficient pregnant women by a new automated kinetic urinary iodine determination method | |
Freeman et al. | Hemoglobin Production Disorders and Testing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06779680 Country of ref document: EP Kind code of ref document: A1 |